These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33943000)

  • 21. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doravirine: its role in HIV treatment.
    Stockdale AJ; Khoo S
    Curr Opin HIV AIDS; 2022 Jan; 17(1):4-14. PubMed ID: 34740228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
    Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF;
    Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2021 Jul; 76(8):2137-2142. PubMed ID: 33855437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Tabassum T; Azeem SM; Muwonge AN; Frey KM
    Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China.
    Lan Y; Xin R; Cai W; Deng X; Li L; Li F; Cai X; Tang X; Fan Q; Hu F
    J Antimicrob Chemother; 2020 Jul; 75(7):1925-1931. PubMed ID: 32300784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
    Boyle A; Moss CE; Marzolini C; Khoo S
    Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?
    Kouamou V; Mavetera J; Manasa J; Ndhlovu CE; Katzenstein D; McGregor AM
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):776-783. PubMed ID: 33430681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.
    Lippman SA; Mooney AC; Puren A; Hunt G; Grignon JS; Prach LM; Gilmore HJ; Truong HM; Barnhart S; Liegler T
    BMC Infect Dis; 2020 Mar; 20(1):248. PubMed ID: 32216752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
    El Bouzidi K; Datir RP; Kwaghe V; Roy S; Frampton D; Breuer J; Ogbanufe O; Murtala-Ibrahim F; Charurat M; Dakum P; Sabin CA; Ndembi N; Gupta RK
    J Antimicrob Chemother; 2022 Feb; 77(2):474-482. PubMed ID: 34741609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug Resistance Mutations in a Population Before Antiretroviral Therapy Initiation in Northern South Africa.
    Ogola B; Matume ND; Mavhandu-Ramarumo LG; Tebit DM; Bessong PO
    AIDS Res Hum Retroviruses; 2022 Mar; 38(3):248-256. PubMed ID: 34107774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa.
    Chimukangara B; Lessells RJ; Sartorius B; Gounder L; Manyana S; Pillay M; Singh L; Giandhari J; Govender K; Samuel R; Msomi N; Naidoo K; de Oliveira T; Moodley P; Parboosing R
    J Glob Antimicrob Resist; 2022 Jun; 29():468-475. PubMed ID: 34785393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
    Zou X; He J; Zheng J; Malmgren R; Li W; Wei X; Zhang G; Chen X
    Virol J; 2020 Mar; 17(1):38. PubMed ID: 32183889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
    Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
    PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
    Ayitewala A; Kyeyune F; Ainembabazi P; Nabulime E; Kato CD; Nankya I
    AIDS Res Ther; 2020 Jan; 17(1):2. PubMed ID: 32005262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Talwani R; Temesgen Z
    Drugs Today (Barc); 2020 Feb; 56(2):113-124. PubMed ID: 32163527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.
    Guerrero-Beltrán C; Martínez-Sanz J; Álvarez M; Olalla J; García-Álvarez M; Iribarren JA; Masiá M; Montero M; García-Bujalance S; Blanco JR; Rivero M; García-Fraile LJ; Espinosa N; Rodríguez C; Aguilera A; Vidal-Ampurdanes MC; Martínez M; Iborra A; Imaz A; Gómez-Sirvent JL; Peraire J; Portilla J; Caballero E; Alejos B; García F; Moreno S;
    J Antimicrob Chemother; 2020 May; 75(5):1294-1300. PubMed ID: 32030406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.